Niigata University Brain Research Institute
Niigata, Niigata, Japan
Manabu Natsumeda
Specially Appointed Associate Professor
Department of Neurosurgery, Brain Research Institute, Niigata University
Languages: Japanese, English (fluent)
Working / Education experience:
Specially Appointed Associate Professor, Department of Neurosurgery, Brain Research Institute, Niigata University (2023- present)
Assistant Professor, Department of Neurosurgery, Brain Research Institute, Niigata University (2013-2023)
Post-doctoral fellow, Department of Pathology, Johns Hopkins University (2013-2016)
Clinical fellow, Department of Neurosurgery, Niigata University (Niigata, Japan) (2009-2011)
Niigata University, Department of Neuropathology, post-graduate course (Ph.D.) (2007-2011)
Resident, Department of Neurosurgery, Niigata University (2007-2009)
Resident, Niigata University, Department of Neurosurgery (2003)
Awards:
Johns Hopkins University Pathology Young Investigator’s Day Award for Excellence in Basic Research (2015)
Sammy’s Award for best English presentation 27th Japanese Neurosurgery English Forum (2012)
Young Investigator Award Niigata University Brain Research Institute Summer Seminar (2010)
Young Investigator Award Niigata University (2009)
Publications:
Book chapters
1. Intrinsic and Skull Base Tumors, 1st edition. Ed Kaisorn L. Chaichana and Alfredo Quinones. Elsevier, 2022.
Original articles (Representative work)
1. Nakata S et al. Natsumeda M (last author, corresponding author). Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastoma sensitive to cisplatin. Neuro-Oncol, 25(5):899-912, 2023.
2. Natsumeda M et al. Susceptibility-weighted imaging by 7-tesla magnetic resonance imaging for the microscopic imaging diagnosis of astrocytic and oligodendroglial tumors. Am J Neuroradiol, 43(11):1575-1581, 2022.
3. Natsumeda M (corresponding author) et al. GLI3 is associated with neuronal differentiation in SHH-activated and WNT-activated medulloblastoma. J Neuropathol Exp Neurol, 80(2):129-136, 2021.
3. Kanemaru Y, Natsumeda M (corresponding author) et al. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun. 7(1):119, 2019.
4. Natsumeda M (corresponding author) et al. Targeting Notch signaling and autophagy increases cytotoxicity in glioblastoma neurospheres. Brain Pathol 26(6):713-723, 2016.
Google Scholar Profile https://scholar.google.co.jp/citations?hl=ja&pli=1&user=IdWucrYAAAAJ
